OSE Immunotherapeutics targets mid-2027 validation for subcutaneous lusvertikimab in IBD
Phase I study submission for the subcutaneous formulation is slated for end-2026, with results expected by mid-2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.